BackEiger BioPharmaceuticals Overview

Eiger BioPharmaceuticals Total Current Liabilities

Track Eiger BioPharmaceuticals's total current liabilities ($53M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$53.28M
112.11% YoYΔ $28.16M vs prior year quarter

Peer average

Loading

Eiger BioPharmaceuticals Total Current Liabilities History

Loading

Eiger BioPharmaceuticals vs. peers: Total Current Liabilities Comparison

Loading

Eiger BioPharmaceuticals Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Eiger BioPharmaceuticals (EIGRQ) FAQ

As of the most recent data (December 2023), EIGRQ shows a total current liabilities of $53M. That compares with $25M in the prior-year period — up 112.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, EIGRQ's total current liabilities is now $53M (was $25M) — a 112.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Eiger BioPharmaceuticals is outperforming or lagging.

Tracking EIGRQ's total current liabilities over time shows whether Eiger BioPharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $53M That compares with $25M in the prior-year period — up 112.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total current liabilities page, Stockcircle has Eiger BioPharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total current liabilities (currently $53M) with ownership activity and broader fundamentals.

Eiger BioPharmaceuticals's total current liabilities is $53M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.